Stock Events

Stock Events

Cerenome 

$1.7079
235
+$0.01+0.46% 11:51 Today

Statistics

Day High
1.71
Day Low
1.68
52W High
19
52W Low
1.49
Volume
2,136
Avg. Volume
-
Mkt Cap
12.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 2Expected
Q1 2026
Q2 2026
Next
-1.31
-1.16
-1
-0.85
Expected EPS
-0.953333
Actual EPS
N/A

Financials

-429.43%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
5.21MRevenue
-22.39MNet Income

Analyst Ratings

$43.67Average Price Target
The highest estimate is ⁦57.00⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CNSY. It's not an investment recommendation.
Amazon
3
AMZN
NVIDIA
3
NVDA
Realty Income
2
O
Coca-Cola
2
KO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mustang Bio
MBIO
Mkt Cap3.03M
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focusing on cell and gene therapies for cancer, directly competing with Plus Therapeutics.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics AG is known for its gene-editing technology applied in cancer therapy, which competes with Plus Therapeutics' approach to cancer treatment.
Fate Therapeutics
FATE
Mkt Cap249.23M
Fate Therapeutics is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders, competing with Plus Therapeutics' focus.
Allogene Therapeutics
ALLO
Mkt Cap407.68M
Allogene Therapeutics, Inc. works on allogeneic CAR T therapies for cancer, a direct competitor to Plus Therapeutics' cancer treatment efforts.

About

Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
Show More
CEO
Marc H. Hedrick
Employees
28
Country
United States
ISIN
US72941H8060
WKN
000A422GY

Listings

XNAS
US
CNSY
F
DE
XMP1.F
MU
DE
XMP1.MU
STU
DE
XMPN.STU

0 Comments

Share your thoughts

FAQs

What is Cerenome stock price today?▼
The current price of CNSY is $1.71 USD — it has increased by +0.46% in the past 24 hours. Watch Cerenome stock price performance more closely on the chart.
What is Cerenome stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cerenome stocks are traded under the ticker CNSY.
What is Cerenome market cap?▼
Today Cerenome has the market capitalization of 12.9M
When is the next Cerenome earnings date?▼
Cerenome is going to release the next earnings report on February 25, 2027.
What is Cerenome revenue for the last year?▼
Cerenome revenue for the last year amounts to 5.21M USD.
What is Cerenome net income for the last year?▼
CNSY net income for the last year is -22.39M USD.
How many employees does Cerenome have?▼
As of November 2, 2026, the company has 28 employees.
In which sector is Cerenome located?▼
Cerenome operates in the Health & Wellness sector.
When did Cerenome complete a stock split?▼
The last stock split for Cerenome was on April 2, 2026 with a ratio of 1:25.
Where is Cerenome headquartered?▼
Cerenome is headquartered in HOUSTON, United States.